Opportunities and challenges of targeting c-met in the treatment of digestive tumors

HIGHLIGHTS

• who: Zhengchao Zhang from the Guangzhou Medical University, China have published the paper: Opportunities and challenges of targeting c-Met in the treatment of digestive tumors, in the Journal: (JOURNAL) of February/28,/2022
• what: This study found that complications of onartuzumab are also the main reasons limiting its widespread use in clinic.
• how: The results showed that Sorafenib combined with chemotherapy significantly improved overall survival and had an acceptable toxic effect compared with single Sorafenib treatment. Chenwei Li et_al evaluated the tumorigenicity of PC cells with high expression of c-Met in . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.